Treatment Study On Macular Edema Secondary To Central Retinal Vein Occlusion By Intravitreal Injection Of Ranibizumab Or Dexamethasone Intravitreal Implant

Objective: To compare the therapeutic efficacy of intravitreal injection of Ranibizumab and Dexamethasone Intravitreal Implant on macular edema secondary to central retinal vein occlusion.Methods: Clinical data of patients with macular edema secondary to central retinal vein occlusion were collected from August 2019 to February2021 in our hospital after the diagnosis by fundus color photography,fundus fluorescence angiography and optical coherence tomography.Intravitreal injection of Ranibizumab group include 26 eyes of 26 patients treated by 3 +PRN therapeutic regimen,and intravitreal injection of Dexamethasone Intravitreal Implant group include 8 eyes of 8 patients treated by 1 + PRN therapeutic regimen.The changes of best corrected visual acuity(BCVA),central macular retinal thickness(CRT)and the incidence of complications were observed and compared before treatment,2 weeks,1 month,2 months,3months and the last follow-up after treatment.Results: There were significant statistical differences in BCVA and CRT of the intravitreal injection of Ranibizumab group at each time point after treatment compared with before treatment(P<0.05).There were also significant statistical differences in BCVA and CRT of the intravitreal injection of Dexamethasone Intravitreal Implant group at each time point after treatment compared with before treatment(P<0.05).There were no significant statistical differences in BCVA and CRT between the two groups at each time point before and after treatment(P>0.05).The intraocular pressure abnormality was found in 3 eyes in the intravitreal injection ofDexamethasone Intravitreal Implant group at 2 months after injection,which could be controlled to normal level only by 1% Blinzosamine eye drops.At 3 months after injection,the intraocular pressure was normal without drugs.There was no intraocular pressure increase in the intravitreal injection of Ranibizumab group at any time points after treatment.Neither serious ocular adverse events such as vitreous hemorrhage,retinal tear,infectious endophthalmitis and rapid development of cataract,nor serious systemic adverse events such as cerebrovascular thrombosis was found after treatment.Conclusions: Intravitreal injection of Ranibizumab or Dexamethasone Intravitreal Implant for treatment of macular edema secondary to central retinal vein occlusion are effective and safe in the shortage study.Compared with intravitreal injection of Ranibizumab,intravitreal injection of Dexamethasone Intravitreal Implant has a relatively longer effective action time,which may reduce the times of injection and the cost of treatment,but has the risk of secondary glaucoma.